Robert C. Sergott, MD

Robert C. Sergott, MD is Chief of the Neuro-Ophthalmology Service at Wills Eye Hospital and Professor of Ophthalmology, Neurology, and Neurosurgery at Sidney Kimmel Medical College.  In addition to these core appointments, Dr. Sergott is also an attending neuro-ophthalmologist at Lankenau Hospital in Philadelphia, and Chief Executive Officer of the Optic Nerve Research Center, headquartered in Claymont, Delaware.

Dr. Sergott earned both his undergraduate and medical degrees at Johns Hopkins University. He then completed a residency in Ophthalmology at Wills Eye and a Neuro-Ophthalmology Fellowship at Bascom-Palmer Eye Institute in Miami. In addition, he was a fellow in Neuro-Immunology and Multiple Sclerosis at the University of Pennsylvania School of Medicine in Philadelphia.

Dr. Sergott’s clinical interests include optic neuropathies and multiple sclerosis, as well as the innovative field of tele-ophthalmology. He is a member of the American Academy of Ophthalmology, the North American Neuro-Ophthalmology Society (NANOS), and the International Neuro-Ophthalmologic Society. In 1996, by vote of the departmental chairs of ophthalmology departments throughout the United States, he was selected as one of the best 100 ophthalmologists in America.

Dr. Sergott has authored over 180 peer-reviewed publications, which included innovative therapies and technologies in the treatment of MS and carotid cavernous fistulas, innovative operative techniques such as optic nerve sheath decompression, and is an expert on new innovations in orbital color Doppler and optical coherence tomography. He has been a Castle Connolly Top Doctor in the USA and a Philadelphia Magazine Top Docs™  for more than 20 years.

Dr. Sergott has received competitive research grant awards from the National Institutes of Health and the National Eye Institute. He is currently involved in multiple clinical trials and grants on the diagnosis and treatment of a variety of neurodegenerative diseases and has represented several sponsors in their successful new drug applications with the United States Food and Drug Administration [FDA] and the European Medicines Agency [EMA].